Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders
08 Enero 2018 - 7:30AM
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) is pleased to
announce the results of the Special Meeting of Stockholders held on
January 5, 2018. Shareholders approved all of the proposed
business matters which included: (i) approval of the second closing
of Anthera’s October 2017 private placement of equity securities
(“PIPE”) transaction bringing total gross proceeds to $15 million;
(ii) approval of the 2018 Stock Option and Incentive Plan; (iii)
approval of the amendment to the 2010 Employee Stock Purchase Plan;
and (iv) ratification of the appointment of BDO USA, LLP as
Anthera’s independent registered public accounting firm for the
fiscal year ending December 31, 2018. Anthera expects to
complete the second closing of the PIPE transaction on or about
January 9, 2018.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a clinical-stage biopharmaceutical
company focused on developing products to treat serious and
life-threatening diseases, including exocrine pancreatic
insufficiency and B-cell associated renal diseases.
Additional information on Anthera can be found at
www.anthera.com.
Safe Harbor Statement
Any statements contained in this press release that refer to
future events or other non-historical matters, including statements
that are preceded by, followed by, or that include such words as
"estimate," "intend," "anticipate," "believe," "plan," "goal,"
"expect," "project," or similar statements, are forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Such
statements are based on Anthera's expectations as of the date
of this press release and are subject to certain risks and
uncertainties that could cause actual results to differ materially,
including but not limited to those set forth in Anthera's public
filings with the SEC, including Anthera's Quarterly Report on
Form 10-Q for the quarter ended September 30, 2017. Anthera
disclaims any intent or obligation to update any forward-looking
statements, whether because of new information, future events or
otherwise, except as required by applicable law.
CONTACT:
Investor Relations of Anthera Pharmaceuticals,
Inc.ir@anthera.com
For Media Inquiries:Frannie Marmorstein,
305-567-0821frannie.marmorstein@rbbcommunications.com
www.twitter.com/antherapharmahttps://www.facebook.com/antherapharma/
https://www.linkedin.com/company/anthera-pharmaceuticals
Source: Anthera Pharmaceuticals, Inc.
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024